The need for novel agents for the treatment of major depression is evidenced by the relatively low remission rates reported with all the FDA-approved antidepressants as well as after treatment with evidence-based psychotherapies such as cognitive behavior therapy (1). After a remarkable hiatus in which no new drugs with any […]